

ЎЗБЕКИСТОН РЕСПУБЛИКАСИ СОҒЛИҚНИ САҚЛАШ ВАЗИРЛИГИ  
ТОШКЕНТ ТИББИЁТ АКАДЕМИЯСИ

2024

2011 йилдан чиқа бошлаган

# TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI



## ВЕСТНИК ТАШКЕНТСКОЙ МЕДИЦИНСКОЙ АКАДЕМИИ

SPECIAL EDITION  
Only English "ADVANCES IN MEDICAL  
RESEARCH AND PRACTICE  
CONFERENCE"

Тошкент



*Выпуск набран и сверстан на компьютерном издательском комплексе*

*редакционно-издательского отдела Ташкентской медицинской академии*

*Начальник отдела: М. Н. Аслонов*

*Редактор русского текста: О.А. Козлова*

*Редактор узбекского текста: М.Г. Файзиева*

*Редактор английского текста: А.Х. Жураев*

*Компьютерная корректура: З.Т. Алюшева*

*Учредитель: Ташкентская медицинская академия*

*Издание зарегистрировано в Ташкентском Городском управлении печати и информации*

*Регистрационное свидетельство 02-00128*

*Журнал внесен в список, утвержденный приказом № 201/3 от 30 декабря 2013года*

*реестром ВАК в раздел медицинских наук*

*Рукописи, оформленные в соответствии*

*с прилагаемыми правилами, просим направлять*

*по адресу: 100109, Ташкент, ул. Фароби, 2,*

*Главный учебный корпус ТМА,*

*4-й этаж, комната 444.*

*Контактный телефон: 214 90 64*

*e-mail: rio-tma@mail.ru*

*rio@tma.uz*

*Формат 60x84 1/8. Усл. печ. л. 9,75.*

*Гарнитура «Cambria».*

*Тираж 150.*

*Цена договорная.*

*Отпечатано на ризографе редакционно-издательского отдела ТМА.*

*100109, Ташкент, ул. Фароби, 2.*

*Вестник ТМА 2024*

## **РЕДАКЦИОННАЯ КОЛЛЕГИЯ**

**Главный редактор**

проф. А.К. Шадманов

**Заместитель главного редактора**

проф. О.Р.Тешаев

**Ответственный секретарь**

проф. Ф.Х.Иноятова

## **ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ**

акад. Аляви А.Л.

проф. Билалов Э.Н.

проф. Гадаев А.Г.

проф. Жае Вук Чои (Корея)

акад. Каримов Ш.И.

проф. Татьяна Силина (Украина)

акад. Курбанов Р.Д.

проф. Людмила Зуева (Россия)

проф. Метин Онерчи (Турция)

проф. Ми Юн (Корея)

акад. Назыров Ф.Г.

проф. Нажмутдинова Д.К.

проф. Саломова Ф.И.

проф. Саша Трескач (Германия)

проф. Шайхова Г.И.

## **ЧЛЕНЫ РЕДАКЦИОННОГО СОВЕТА**

проф. Акилов Ф.О. (Ташкент)

проф. Аллаева М.Д. (Ташкент)

проф. Хамдамов Б.З. (Бухара)

проф. Ирискулов Б.У. (Ташкент)

проф. Каримов М.Ш. (Ташкент)

проф. Маматкулов Б.М. (Ташкент)

проф. Охунов А.О. (Ташкент)

проф. Парпиева Н.Н. (Ташкент)

проф. Рахимбаева Г.С. (Ташкент)

проф. Хамраев А.А. (Ташкент)

проф. Холматова Б.Т. (Ташкент)

проф. Шагазатова Б.Х. (Ташкент)

*Herald TMA 2024*

**EDITORIAL BOARD**

**Editor in chief**

prof. A.K. Shadmanov

**Deputy Chief Editor**

prof. O.R. Teshaev

**Responsible secretary**

prof. F.Kh. Inoyatova

**EDITORIAL TEAM**

academician Alyavi A.L.

prof. Bilalov E.N.

prof. Gadaev A.G.

prof. Jae Wook Choi (Korea)

academician Karimov Sh.I.

prof. Tatyana Silina (Ukraine)

academician Kurbanov R.D. prof. Lyudmila Zueva (Russia)

prof. Metin Onerc (Turkey)

prof. Mee Yeun (Korea)

prof. Najmutdinova D.K.

prof. Salomova F.I.

prof. Sascha Treskatch (Germany)

prof. Shaykhova G.I.

**EDITORIAL COUNCIL**

DSc. Abdullaeva R.M.

prof. Akilov F.O. (Tashkent)

prof. Allaeva M.D. (Tashkent)

prof. Khamdamov B.Z. (Bukhara)

prof. Iriskulov B.U. (Tashkent)

prof. Karimov M.Sh. (Tashkent)

prof. Mamatkulov B.M. (Tashkent)

prof. Okhunov A.A. (Tashkent)

prof. Parpieva N.N. (Tashkent)

prof. Rakhimbaeva G.S. (Tashkent)

prof. Khamraev A.A. (Tashkent)

prof. Kholmatova B.T. (Tashkent)

prof. Shagazatova B.X. (Tashkent)

*Journal edited and printed in the computer of Tashkent  
Medical Academy editorial department*

*Editorial board of Tashkent Medical Academy*

*Head of the department: M.N. Aslonov*

*Russian language editor: O.A. Kozlova*

*Uzbek language editor: M.G. Fayzieva*

*English language editor: A.X. Juraev*

*Corrector: Z.T. Alyusheva*

*Organizer: Tashkent Medical Academy*

*Publication registered in editorial and information  
department of Tashkent city*

*Registered certificate 02-00128*

*Journal approved and numbered under the order 201/3 from 30 of  
December 2013 in Medical Sciences department OF SUPREME ATTESTATION*

**COMMISSION**

**COMPLETED MANUSCRIPTS PLEASE SEND following address:**

*2-Farobiy street, 4 floor room 444. Administration building of TMA.  
Tashkent. 100109, Toshkent, ul. Farobi, 2, TMA bosh o'quv binosi, 4-qavat,  
444-xona.*

*Contact number: 71- 214 90 64*

*e-mail: rio-tma@mail.ru. rio@tma.uz*

*Format 60x84 1/8. Usl. printer. I. 9.75.*

*Listening means «Cambria».*

*Circulation 150.*

*Negotiable price*

*Printed in TMA editorial and publisher department risograph*

*2 Farobiy street, Tashkent, 100109.*

concentration of uric acid [9]. It is assumed that aseptic microcrystalline inflammation in gout with the formation of sodium monourate crystals and their deposition in internal organs can lead to activation of vascular-platelet haemostasis [10,11].

Thus, a large-scale study (Papavasileiou et al., 2023) investigated the relationship of MC with: fibrinogen, international normalised ratio (INR), homocysteine, antithrombin III, D-dimer and plasminogen activator inhibitor-1 (PAI-1). According to the results of their study it was proved that, fibrinogen, INR, homocysteine, D-dimer and PAI-1 are positively correlated with uric acid levels in hypertensive patients, while Antithrombin III is negatively correlated with uric acid levels. Multivariate regression analysis showed that fibrinogen, homocysteine, D-dimer are independent predictors of uric acid [12].

Thus, according to a number of authors there is a relationship between gout and disorders in the haemostasis system.

### References

1. Gout and the risk of acute myocardial infarction / E Krishnan [et al.] // Arthritis Rheum. - 2006. - Vol. 54. - P. 2688-2696.
2. Rao, G.N., Corson, M.A. and Berk, B.C. (1991) Uric Acid Stimulates Vascular Smooth Muscle Cell Proliferation by Increasing Platelet-Derived Growth Factor A-Chain Expression. Journal of Biological Chemistry, 266, 8604-8608. [https://doi.org/10.1016/S0021-9258\(18\)93017-6](https://doi.org/10.1016/S0021-9258(18)93017-6)
3. Kanellis, J., Watanabe, S., Li, J.H., et al. (2003) Uric Acid Stimulates Monocyte Chemo Attractant Protein-1 Production in Vascular Smooth Muscle Cells via Mito- gen-Activated Protein Kinase and Cyclooxygenase-2. Hypertension, 41, 1287-1293. <https://doi.org/10.1161/01.HYP.0000072820.07472.3B>
4. Langlois, M., De Bacquer, D., Duprez, D., et al. (2003) Serum Uric Acid in Hyper- tensive Patients with and without Peripheral Arterial Disease. Atherosclerosis, 168, 163-168. [https://doi.org/10.1016/S0021-9150\(03\)00093-5](https://doi.org/10.1016/S0021-9150(03)00093-5)
5. Kang, D.H., Finch, J., Nakagawa, T., et al. (2004) Uric Acid, Endothelial Dysfunc- tion and Pre-Eclampsia: Searching for a Pathogenetic Link. Journal of Hyperten- sion, 22, 229-235. <https://doi.org/10.1097/00004872-200402000-00001>
6. Patetsios, P., Song, M., Shutze, W.P., et al. (2001) Identification of Uric Acid and Xanthine Oxidase in Atherosclerotic Plaque. American Journal of Cardiology, 88, 188-191. [https://doi.org/10.1016/S0002-9149\(01\)01621-6](https://doi.org/10.1016/S0002-9149(01)01621-6)
7. Viazzi, F., et al. (2005) Serum Uric Acid and Target Organ Damage in Primary Hypertension. Hypertension, 45, 991-996. <https://doi.org/10.1161/01.HYP.0000161184.10873.ea>
8. Zuo, T., Liu, X.H., Jiang, L., et al. (2016) Hyperuricemia and Coronary Heart Dis- ease Mortality: A Meta-Analysis of Prospective Cohort Studies. BMC Cardiovascu- lar Disorders, 16, 207. <https://doi.org/10.1186/s12872-016-0379-z>
9. Mengghini, P. and Bellotti, R. (1955) La Trombofiebile gullosa. Min Med, 1, 116-119.

## OPTIMIZATION OF DIAGNOSTIC AND TREATMENT TACTICS FOR BENIGN OBSTRUCTION OF THE EXTRAHEPATIC BILE DUCTS

Khakimov M.Sh., Ashurov Sh.E., Davlatov U.Kh.

*Tashkent medical academy, Tashkent, Uzbekistan*

**Key words:** choledocholithiasis, “intermediate” condition, obstructive jaundice, postcholecystectomy syndrome, retrograde endobiliary interventions, cholangiopancreatography, papilla sphincterotomy.

**Objective:** To improve treatment outcomes for patients with suspected pathology of the extrahepatic bile ducts (“intermediate condition”) by optimizing diagnostic and tactical approaches to performing retrograde endobiliary interventions.

**Materials and Methods:** The study analyzed the examination and treatment results of 697 patients who underwent inpatient treatment in the thoracoabdominal and emergency surgery departments of the multidisciplinary clinic at Tashkent Medical Academy from 2011 to 2023, and who underwent retrograde endobiliary interventions (REI). The age range was 18 to 85 years, with a predominance of females (the male-to-female ratio was 1:1.5). All patients were divided into two clinical groups: control and main. The control group included 300 patients treated from 2011 to 2018, who underwent REI based on suspected extrahepatic bile duct pathology. The main group consisted of 397 patients admitted to the clinic since 2019, where a newly developed algorithm for managing patients with extrahepatic bile duct pathology was used.

**Results:** The treatment outcomes of 697 patients with signs of choledocholithiasis, complicated by benign obstructive jaundice or without signs of jaundice, were presented. The developed algorithm for managing patients with “intermediate” conditions allowed for the specification of indications for retrograde endoscopic interventions. A differentiated approach to performing REI, taking into account the risk of bleeding from the papillotomy area, acute pancreatitis, and the severity of the upcoming manipulation, reduced the incidence of post-procedural complications by 2.4 times and mortality by 4.5 times.

**Conclusion:** The specification of indications for retrograde interventions in “intermediate” conditions reduced the frequency of unnecessary endoscopic retrograde interventions by 17.4%, and the incidence of post-procedural complications and mortality by 2.4 and 4.5 times, respectively.

## DEVELOPMENT AND OPTIMIZATION OF TREATMENT TACTICS FOR BLEEDING FROM THE PAPILOTOMY ZONE DURING RETROGRADE INTERVENTIONS

Khakimov M.Sh., Ashurov Sh.E., Davlatov U.Kh.

*Tashkent medical academy, Tashkent, Uzbekistan*

**Key words:** Bleeding from the EPST zone, hemostasis methods, endoscopic clipping.

**Objective:** To improve treatment outcomes for patients with bleeding from the EPST (endoscopic papillosphincterotomy) zone by optimizing treatment tactics.

**Materials and Methods:** The study involved 510 patients who were admitted to the emergency surgery department of the multidisciplinary clinic of Tashkent Medical Academy between 2015 and 2022 with mechanical jaundice caused by extrahepatic duct stones. The age of the patients ranged from 18 to 90 years, with a predominance of females (318 women, 62.4%) and males (192 men, 37.6%). A comparative analysis was conducted between the results of treatment in the control group (210 patients) and the main group (300 patients).

**Results:** In the control group, bleeding was observed in 25 (12.0%) out of 210 patients, with definitive hemostasis achieved in 20 (80%) cases. The remaining 5 (20%) patients required open surgical intervention after repeated attempts at endoscopic hemostasis, leading to delayed treatment and deterioration in the overall condition of these patients. Of these, 2 cases resulted in fatality due to hemorrhagic shock in the early postoperative period. The analysis of treatment outcomes in the control group revealed that the unsatisfactory results were due to a lack of clear tactics during bleeding, as well as the absence of a clear classification of bleeding intensity levels, which may have negatively affected the choice of endoscopic hemostasis method and surgical interventions. These results necessitated the development of a classification system for assessing bleeding intensity, influencing the selection of the hemostasis method for this EPST complication.

In the main group, 47 (15.7%) out of 300 patients experienced bleeding from the EPST zone. The analysis showed the following distribution of bleeding severity: 1st-degree bleeding in 8 (17.0%) cases, 2nd-degree bleeding in 14 (29.8%) cases, and 3rd-degree bleeding in 25 (53.2%) cases. All patients were treated according to the aforementioned algorithm, yielding the following results: in patients with 1st-degree bleeding, definitive endoscopic hemostasis was achieved in 6 (75%) cases; in 2 cases, duodenotomy with suturing of the bleeding EPST zone was performed, and 1 patient developed duodenal stump dehiscence, which healed with conservative measures. All patients with 2nd-degree bleeding were discharged 3-4 days after endoscopic hemostasis. In patients with 3rd-degree bleeding, definitive hemostasis was achieved in all cases without recurrence of bleeding. No deaths due to bleeding were observed in the main group.

**Conclusion:** The use of an optimal treatment algorithm for bleeding from the papillosphincterotomy zone increased the success rate of endoscopic hemostasis to 95.7%, reducing the number of open surgeries and lowering the mortality rate from 20% to 4.3% and from 1.0% to 0%, respectively.

## THE INFLUENCE OF HYPERPARATHYROIDISM ON THE APPEARANCE OF PANCREATITIS

Botirova A.N

*Tashkent medical academy, Tashkent, Uzbekistan*

**Aim:** Examine the effects of hyperparathyroidism on alterations in the gastrointestinal system.

**Methods and materials:** The study involved a retrospective review of medical records from 68 patients with hyperparathyroidism. The following symptoms are indicative of gastrointestinal disturbances that can be associated with hypercalcemia, a hallmark of hyperparathyroidism: 82% of patients experienced frequent heartburn; 75% reported constipation; 15% experienced nausea; and 60% experienced a loss of appetite. Notably, 65% of patients initially sought consultation from a gastroenterologist due to these gastrointestinal complaints, and were subsequently diagnosed with pancreatitis.

**Results:** The main way that hyperparathyroidism affects the gastrointestinal tract is by causing hypercalcemia, which can change how the pancreas and other GI organs function. The following are the hypothesized mechanisms by which hyperparathyroidism affects the course of pancreatitis:

1. Calcium-Induced Activation of Pancreatic Enzymes: High calcium concentrations have the potential to trigger the early activation of pancreatic enzymes, resulting in the autodigestion of pancreatic tissue and consequent pancreatitis.
2. Deposits and Ductal Obstruction: High blood calcium levels can cause calcium deposits to form in the pancreatic ducts, which impede the flow of pancreatic secretions and raise the risk of pancreatitis and inflammation.
3. Gastrointestinal Motility Disorders: Constipation, nausea, and changes in bowel habits are among the symptoms that can result from hypercalcemia's impact on smooth muscle function. These signs may conceal the underlying pancreatitis or cause a delay in its identification.

**Conclusion.** The gastrointestinal tract can be greatly impacted by hyperparathyroidism, which frequently manifests as symptoms that resemble those of primary gastrointestinal disorders. The significance of taking endocrine causes into account when evaluating gastrointestinal complaints is highlighted by the high incidence of pancreatitis among patients with hyperparathyroidism. Prompt identification and management of hyperparathyroidism can enhance patient outcomes by averting recurrent pancreatitis

**Literature:**



Содержание	
<b>I. SECTION. THERAPY3</b>	
Abdullayeva M.I., Inoyatova F.Kh., Matchanov A., Ulugbek Zaribbayevich, Mirakhmedova K.G. PHARMACOLOGICAL CORRECTION OF FATTY LIVER DISEASE BY SUPRAMOLECULAR COMPLEXES OF GALLIC ACID	4
Nabieva D.A, Akramova N.T, Aditya Kush PATHOPHYSIOLOGICAL BASES OF THE RELATIONSHIP BETWEEN GOUT AND HAEMOSTASIS DISORDERS	4
Khakimov M.Sh., Ashurov Sh.E., Davlatov U.Kh. OPTIMIZATION OF DIAGNOSTIC AND TREATMENT TACTICS FOR BENIGN OBSTRUCTION OF THE EXTRAHEPATIC BILE DUCTS	5
Khakimov M.Sh., Ashurov Sh.E., Davlatov U.Kh. DEVELOPMENT AND OPTIMIZATION OF TREATMENT TACTICS FOR BLEEDING FROM THE PAPILLOTOMY ZONE DURING RETROGRADE INTERVENTIONS	6
Botirova A.N THE INFLUENCE OF HYPERPARATHYROIDISM ON THE APPEARANCE OF PANCREATITIS	6
Saidrasulova G.B., Kalash D., Rahmonova U.T. CASE REPORT: DIFFUSE SYSTEMIC SCLEROSIS WITH ACUTE SUBACUTE ONSET COMPLICATED BY MULTI-ORGAN INVOLVEMENT, APPROACH TO TREATMENT AND MANAGEMENT	7
Toshmatova.M.B CHILDREN CEREBRAL PALSY.SPASTIC DIPLEGIA	7
Saidrasulova G.B., Janani Velu TREATMENT OPTIONS FOR DYSLIPIDEMIA IN CHRONIC KIDNEY DISEASES	9
Miraxmedova X.T. Aybergenova X.Sh. DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF CLINICAL, LABORATORY AND IMMUNOLOGICAL INDICATORS IN KIDNEY DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS	10
Akhmedova M.D. Imamova I.A., Karimova M.T., Mirzaeva G.A. EXPLORING THE IMMUNOLOGICAL INTERACTION OF ASCARIDA AND H. PYLORI	11
Gaibnazarov S.S., Sayfiddin Q.Sh. Hoji, Saparbayeva J.S., Magrupov T.M. DEVELOPMENT OF A NEURAL NETWORK COMPLEX FOR EARLY THERAPEUTIC DIAGNOSTICS OF LUNG DISEASES	11
Baltabaeva G.Sh. HYPERPROLACTINEMIA AND PREGNANCY	12
Ibragimova D.Y., Umarova F.N. CLINICAL AND ORGANIZATIONAL FEATURES AND DEVELOPMENT OF A SYSTEM FOR PROVIDING SPECIALIZED MEDICAL CARE TO PATIENTS WITH VIRAL PNEUMONIA CAUSED BY SARS-COV-2»	13
Ikramova S. "APPROACH TO ASSESSING THE RISK OF COMPLICATIONS FROM CORONAVIRUS INFECTION IN PATIENTS WITH EPILEPSY"	13
Makhkamova M.M., Nurillayeva N.M. PREVALENCE OF METABOLIC DYSFUNCTION IN POSTMENOPAUSAL WOMEN DIAGNOSED WITH CORONARY ARTERY DISEASE	14
Bobonazarova M. N, Matkarimova D. S. RESISTANCE TO TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA	14
Mamadjanova Kh.Kh. RISK FACTORS FOR OSTEOPOROSIS IN PATIENTS WITH TYPE 2 DIABETES	15
Mamadjanova Kh.Kh., Mirzayeva Kh.A. CLINICAL MANIFESTATIONS OF OSTEOPAROSIS IN PATIENTS WITH TYPE 2 DIABETUS MELLITUS	15
Mirzaumarova F.T., Ibodullaeva M.A., R. Q. Karakhanov. VARIOUS HEMODYNAMICS OF CHRONIC H EART FAILURE ROLE OF ALDOSTERONE IN ASSESSMENT OF FIBROSIS PROCESSES	16
Saddam Shaikh. NOVEL AND EMERGING THERAPIES FOR INFLAMMATORY BOWEL DISEASE (IBD)	16
Nuriddinova N.F., Kurbonova Z.Ch., Zaynutdinova D.L. IMPORTANCE OF ENDOTHELIAL MARKERS IN PATIENTS WITH CHRONIC HEPATITIS C AND LIVER CIRRHOSIS.	18
Muxamediyeva I.B. THE EFFECT OF ISOQUINOLINE ALKALOIDS F-4 AND F-24 ON THE DYSFUNCTION OF RAT HEART MITOCHONDRIA UNDER CONDITIONS OF OXIDATIVE STRESS	18
Riddhi Shailendra Mishra, M.Sh.Abduljalilova. PSYCHOEMOTIONAL BACKGROUND IN CHILDREN WITH BRONCHIAL ASTHMA	19
Gafurova D.S., Inoyatova F.X. THE EFFECT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON THYROID FUNCTION	20
Mirakhmedova Kh.T., Nizametdinova U.J. Saidrasulova G.B. THE EFFECT OF HYPERURICEMIA IN PATIENTS WITH OSTEOARTHRITIS AND METABOLIC SYNDROME.	20
Jumanazarova A.J. OBESITY - THE BASIS OF METABOLIC SYNDROME	21
Najmutdinova D.K., Sadikova A.S. MODERN METHODS OF TREATING OBESITY	21
Abdullayev R. B., Bakhtiyarova A. M. THERAPEUTIC AND DIETIC NUTRITION MANAGEMENT FOR ULCER DISEASE IN THE KHOREZM REGION	22
Matkarimov O.I., Akhmedova S.M. , Niyozov N.Q. MYOCARDIAL MORPHOLOGY ON THE BACKGROUND OF DIABETES	23